The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes

被引:0
|
作者
Wilson, Jonathan M.
Lin, Yanzhu
Considine, Gary
Cox, Amy L.
Bowsman, Lenden M.
Robins, Deborah A.
Riesmeyer, Jeffrey S.
Haupt, Axel
Duffin, Kevin
Ruotolo, Giacomo
机构
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A13426
引用
收藏
页数:2
相关论文
共 50 条
  • [1] The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
    Wilson, J. M.
    Nikooienejad, A.
    Bowsman, L. M.
    Schroeder, J. M.
    Hamlin, D. M.
    Robins, D. A.
    Riesmeyer, J. S.
    Haupt, A.
    Duffin, K. L.
    Ruotolo, G.
    [J]. DIABETOLOGIA, 2019, 62 : S558 - S559
  • [2] THE DUAL GIP AND GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES (T2D)
    Wilson, J.
    Nikooienejad, A.
    Lin, Y.
    Robins, D.
    Roell, W.
    Riesmeyer, J.
    Haupt, A.
    Duffin, K.
    Ruotolo, G.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A164 - A165
  • [3] Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    Hartman, Mark L.
    Sanyal, Arun J.
    Loomba, Rohit
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Karanikas, Chrisanthi A.
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    [J]. DIABETES CARE, 2020, 43 (06) : 1352 - 1355
  • [4] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    [J]. JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [5] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes
    Ruotolo, G.
    Roth, K. D.
    Milligan, P. L.
    Lin, Y.
    Wilson, J. M.
    Pirro, V
    Duffin, K. L.
    Haupt, A.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3056 - 3056
  • [6] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes
    Pirro, V.
    Willency, J. A.
    Wilson, J. M.
    Roth, K. D.
    Lin, Y.
    Collins, K. A. L.
    Ruotolo, G.
    Haupt, A.
    Newgard, C. B.
    Duffin, K. L.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S73 - S73
  • [7] Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta cell function and insulin sensitivity in type 2 diabetes patients
    Thomas, M. K.
    Nikooienejad, A.
    Bray, R.
    Cui, X.
    Wilson, J.
    Duffin, K.
    Milicevic, Z.
    Haupt, A.
    Robins, D. A.
    [J]. DIABETOLOGIA, 2019, 62 : S354 - S354
  • [8] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan
    Duffin, Kevin
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : 388 - 396
  • [9] Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
    Willard, Francis S.
    Douros, Jonathan D.
    Gabe, Maria
    Showalter, Aaron D.
    Wainscott, David B.
    Suter, Todd M.
    Capozzi, Megan E.
    van der Velden, Wijnand J. C.
    Stutsman, Cynthia
    Cardona, Guemalli R.
    Urva, Shweta
    Emmerson, Paul J.
    Holst, Jens J.
    D'Alessio, David A.
    Coghlan, Matthew P.
    Rosenkilde, Mette M.
    Campbell, Jonathan E.
    Sloop, Kyle W.
    [J]. JCI INSIGHT, 2020, 5 (17)
  • [10] Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan M.
    Duffin, Kevin L.
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    [J]. DIABETES, 2019, 68